NIH taps Genentech drug for pioneering Alzheimer's study

The NIH will help fund a landmark, $100 million study of Genentech's experimental Alzheimer's treatment crenezumab. Researchers will test the drug in Colombians with a particular genetic mutation, aiming to see if the drug can stop Alzheimer's before it starts. Report